Write in a clean editor, then format for Gynecologic Oncology Research and Practice in one click — DocuGuru applies the official BMC (BioMed Central) template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Gynecologic Oncology Research and Practice is a peer-reviewed journal published by BMC (BioMed Central), covering Endometrial and Cervical Cancer Treatments, Ovarian cancer diagnosis and treatment, Cervical Cancer and HPV Research.
| Publisher | BMC (BioMed Central) |
|---|---|
| Reference style | Numbered (Vancouver) Numbered — [1], [2] in the text 1. Smith A, Jones B, Lee C. A representative article title. Gynecologic Oncology Research and Practice. 2023;12(3):45–58.
Formats any DOI in Gynecologic Oncology Research and Practice style. No sign-up. |
| Publishes research in | Endometrial and Cervical Cancer Treatments Ovarian cancer diagnosis and treatment Cervical Cancer and HPV Research PARP inhibition in cancer therapy BRCA gene mutations in cancer |
| ISSN | 2053-6844 |
| h-index | 25 |
| i10-index | 44 |
| Total citations | 2,164 |
| Top institutions publishing here | University of Arizona |
| Journal website | gynoncrp.biomedcentral.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Endometrial carcinoma (EC) is the fourth most common cancer in women in the developed world. Classification of ECs by histomorphologic criteria has limited reproducibility and better tools are needed to distinguish these tumors and enable a subtype-specific approach to research and clinical care. Based on the Cancer Genome Atlas, two research teams have developed pragmatic…
The introduction of immune checkpoint inhibitors has revolutionized treatment of multiple cancers and has bolstered interest in this treatment approach. So far, emerging clinical data show limited clinical efficacy of these agents in ovarian cancer with objective response rates of 10-15% with some durable responses. In this review, we present emerging clinical data of completed…
genes. However, through germline and tumor sequencing an understanding of the larger phenomenon of homologous recombination deficiency (HRD) has emerged. HRD impairs normal DNA damage repair which results in loss or duplication of chromosomal regions, termed genomic loss of heterozygosity (LOH). The list of inherited mutations associated with ovarian cancer continues to grow with the…
Endometrial cancer is the most common gynecologic malignancy in the United States, accounting for 6% of cancers in women. In 2017, an estimated 61,380 women were diagnosed with endometrial cancer, and approximately 11,000 died from this disease. From 1987 to 2008, there was a 50% increase in the incidence of endometrial cancer, with an approximate…
Combretastatin A4-phosphate (CA4P) is a vascular-disrupting agent (VDA) in clinical development for the treatment of ovarian and other cancers. In contrast to antiangiogenic agents, such as bevacizumab, which suppress the development of new tumor vasculature, VDAs target established tumor vasculature. These differing but complementary mechanisms of action are currently being explored in clinical trials combining…
